Last reviewed · How we verify

CARUMONAM — Competitive Intelligence Brief

CARUMONAM (CARUMONAM) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: carumonam. Area: Metabolic.

marketed carumonam Peptidoglycan synthase FtsI Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

CARUMONAM (CARUMONAM).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CARUMONAM TARGET CARUMONAM marketed carumonam Peptidoglycan synthase FtsI
Ceftazidim Ceftazidim Tel-Aviv Sourasky Medical Center marketed Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Moxam latamoxef Eli Lilly marketed latamoxef Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (carumonam class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CARUMONAM — Competitive Intelligence Brief. https://druglandscape.com/ci/carumonam. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: